Off-target toxicity: Risks associated with adrenal corticoid activation in ILLUMINATE
Clinical Trials Report
- First Online:
- 17 Downloads
Unable to display preview. Download preview PDF.
- 5.McKenney JM, Davidson MH, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006, 48:1782–1790.PubMedCrossRefGoogle Scholar
- 6.Pfizer Inc.: In interests of patients safety, Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities. Pfizer news release. December 2, 2006. Available at http://www.fda.gov/bbs/topics/NREWS/2006/NEW0154.html. Accessed October 30, 2007.
- 10.Forrest MJ, Sparrow CP: Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levels. Paper presented at American Heart Association Scientific Sessions. Orlando, FL; November 4–7, 2007.Google Scholar
- 11.Keidar S, Kaplan M, Pavlotzky E, et al.: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213–2220.PubMedCrossRefGoogle Scholar
© Current Medicine Group LLC 2008